Thanks for your feedback, this will help us improve our content for you!
Thank for your feedback, this will help us improve our content for you!
Dr Joseph Mikhael discusses the results of the ENDEAVOR trial, a phase 3 head-to-head study that demonstrates superiority of carfilzomib over bortezomib in patients with relapsed multiple myeloma.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter